Menu Search
Equities

Cutia Therapeutics

2487:HKG

Cutia Therapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)8.34
  • Today's Change0.04 / 0.48%
  • Shares traded427.20k
  • 1 Year change-59.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Cutia Therapeutics had net income fall 253.30% from a loss of 555.84m to a larger loss of 1.96bn despite a 1,110.83% increase in revenues from 11.37m to 137.62m. An increase in the cost of goods sold as a percentage of sales from 30.16% to 48.40% was a component in the falling net income despite rising revenues.
Gross margin50.33%
Net profit margin-263.68%
Operating margin-259.86%
Return on assets-31.81%
Return on equity-37.39%
Return on investment-35.82%
More ▼

Cash flow in CNYView more

In 2023, Cutia Therapeutics did not generate a significant amount of cash. Cash Flow from Financing totalled 588.32m or 427.49% of revenues. In addition the company used 381.31m for operations while cash used for investing totalled 203.58m.
Cash flow per share-1.70
Price/Cash flow per share--
Book value per share4.19
Tangible book value per share4.16
More ▼

Balance sheet in CNYView more

Cutia Therapeutics appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio5.09
Quick ratio4.82
Total debt/total equity0.2222
Total debt/total capital0.1818
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.